Story content courtesy of B3C Newswire, DE
Biotech company ExpreS2ion Biotechnologies today announced that they have signed a research license agreement to provide the University of Oxford access to ExpreS2ion’s Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production. The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford.
This license is an example of ExpreS2ion Biotechnologies’ vision of making its production platform available to academic centers of excellence globally, in complement to the Company’s strategy of making S2 one of the standard protein production platforms in the vaccine and therapeutic protein segments.
ExpreS2ion Biotechnologies has developed a complete proprietary protein expression platform, ExpreS2, based on engineered Drosophila Schneider-2 (S2) cells to serve recombinant protein production needs in the biopharmaceutical industry as well as in academia.
The Jenner Institute is a research partnership between the University of Oxford and the Pirbright Institute (formerly Institute for Animal Health). The Institute focuses on the parallel development of human and veterinary vaccines against major global diseases - from early-stage research through to clinical trials.